neurimmune.com

Neurimmune - Home

Severe and Rare Diseases. Severe and Rare Diseases. Phase 3 clinical trials. Program for Parkinson in Phase 1. Creating an entirely novel. Generation of drugs with. Excellent safety and efficacy. January 25, 2018. In January 2018, Biogen dosed the first patient in the Phase 2 SPARK study of BIIB054 (anti-alpha-synuclein antibody) in Parkinson's disease. November 9, 2017. Neurimmune Announces Collaboration with Ono Pharmaceutical in Neurodegenerative Diseases Field. October 24, 2017. Neurimmune’s program ...

http://www.neurimmune.com/

OVERVIEW OF neurimmune.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

18

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR NEURIMMUNE.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

December

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Tuesday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 3.8 out of 5 with 13 reviews

5 star

4

4 star

4

3 star

4

2 star

0

1 star

1

Hey there! Start your review of neurimmune.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

1.2 seconds

FAVICON PREVIEW

16x16
32x32

CONTACTS AT NEURIMMUNE.COM

Neurimmune Holding AG

Karim Giopp

Wagis●●●●●se 13

Sch●●●ren , 8952

CH

41.●●●610

41.●●●647

it●●●●●●●@neurimmune.com

View this contact

Neurimmune Holding AG

Karim Giopp

Wagis●●●●●se 13

Sch●●●ren , 8952

CH

41.●●●610

41.●●●647

it●●●●●●●@neurimmune.com

View this contact

Neurimmune Holding AG

Karim Giopp

Wagis●●●●●se 13

Sch●●●ren , 8952

CH

41.●●●610

41.●●●647

it●●●●●●●@neurimmune.com

View this contact

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

DOMAIN REGISTRATION INFORMATION

REGISTERED: 2006 October 02
UPDATED: 2013 August 14
EXPIRATION: EXPIRED REGISTER THIS DOMAIN

BUY YOUR DOMAIN

DOMAIN AGE

17

YEARS
7

MONTHS
4

DAYS

NAME SERVERS

1: ns1.nexlink.ch
2: ns2.nexlink.ch

REGISTRAR

COREHUB, S.R.L.

WHOIS : whois.corehub.net

REFERRED : http://www.corehub.net

CONTENT

PAGES IN
THIS WEBSITE

18

SSL

EXTERNAL LINKS

4

SITE IP

80.86.198.12

LOAD TIME

1.234 sec

SCORE

6.2

PAGE TITLE

Neurimmune - Home | neurimmune.com Reviews

<META> DESCRIPTION

Severe and Rare Diseases. Severe and Rare Diseases. Phase 3 clinical trials. Program for Parkinson in Phase 1. Creating an entirely novel. Generation of drugs with. Excellent safety and efficacy. January 25, 2018. In January 2018, Biogen dosed the first patient in the Phase 2 SPARK study of BIIB054 (anti-alpha-synuclein antibody) in Parkinson's disease. November 9, 2017. Neurimmune Announces Collaboration with Ono Pharmaceutical in Neurodegenerative Diseases Field. October 24, 2017. Neurimmune’s program ...

<META> KEYWORDS

1 about neurimmune

2 management

3 board of directors

4 advisory board

5 technology

6 rtm technology platform

7 scientific background

8 product pipeline

9 alzheimer’s disease

10 parkinson’s disease

CONTENT

Page content here

KEYWORDS ON PAGE

about neurimmune,management,board of directors,advisory board,technology,rtm technology platform,scientific background,product pipeline,alzheimer’s disease,parkinson’s disease,type 2 diabetes,partnering,strategy,industry partnerships,careers,media,welcome

SERVER

Apache/2

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

Neurimmune - Home | neurimmune.com Reviews

https://neurimmune.com

Severe and Rare Diseases. Severe and Rare Diseases. Phase 3 clinical trials. Program for Parkinson in Phase 1. Creating an entirely novel. Generation of drugs with. Excellent safety and efficacy. January 25, 2018. In January 2018, Biogen dosed the first patient in the Phase 2 SPARK study of BIIB054 (anti-alpha-synuclein antibody) in Parkinson's disease. November 9, 2017. Neurimmune Announces Collaboration with Ono Pharmaceutical in Neurodegenerative Diseases Field. October 24, 2017. Neurimmune’s program ...

INTERNAL PAGES

neurimmune.com

1

Neurimmune - Board of Directors

http://www.neurimmune.com/company/board-of-directors.html

Severe and Rare Diseases. Severe and Rare Diseases. The Board of Directors has in-depth knowhow in drug development in the pharmaceutical and biotech industry. Roger Nitsch, MD. President of the Board. Jan Grimm, PhD. Member of the Board. Christoph Hock, MD. Neurimmune Holding AG ,. Wagistrasse 13 ,. CH-8952 Schlieren-Zurich ,.

2

Neurimmune - News

http://www.neurimmune.com/media/news.html

Severe and Rare Diseases. Severe and Rare Diseases. June 1, 2016. Aducanumab accepted into EMA's PRIME Program. February 3, 2016. BIIB076 (anti-tau mAb) moving into pre-IND toxicology studies. November 10, 2015. Neurimmune’s data on its broadly neutralizing human monoclonal JC polyomavirus VP1 specific antibodies as candidate therapeutics for PML published in Science Translational Medicine. October 27, 2015. September 8, 2015. July 28, 2015. July 22, 2015. July 2, 2015. March 20, 2015. January 12, 2015.

3

Neurimmune - Alzheimer’s Disease

http://www.neurimmune.com/products/alzheimers-disease.html

Severe and Rare Diseases. Severe and Rare Diseases. We are entirely devoted to prevent, treat and finally hopefully eradicate Alzheimer's disease and other neurodegenerative conditions, by the end of 2025. Christoph Hock, MD. Neurimmune aims at the development of disease-modifying treatments for Alzheimer’s disease, and partnered its first RTM. In 2010, Neurimmune also partnered its second AD program BIIB076 on recombinant human monoclonal antibodies targeting tau with Biogen. Biogen presents the first c...

4

Neurimmune - Working at Neurimmune

http://www.neurimmune.com/careers/working-at-neurimmune.html

Severe and Rare Diseases. Severe and Rare Diseases. Consider joining Neurimmune and becoming part of the exciting future of pharmaceutical biotechnology. Currently there are no open positions. We are a financially strong company with a highly independent philosophy and wish to bring the best talent to our team. Our employees enjoy an outstanding scientific environment allied with a range of professional and personal development programs. Contact for Human Resources:. Christine Frei, HR. Wagistrasse 13 ,.

5

Neurimmune - 22.07.2015: Biogen Presents New Data from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at Alzheimer’s Association International Conference® 2015

http://www.neurimmune.com/newsartikel/22072015-biogen-presents-new-data-from-phase-1b-study-of-investigational-alzheimers-disease-treatment-aducanumab-biib037-at-alzheimers-association-international-conference-2015.html

Severe and Rare Diseases. Severe and Rare Diseases. July 22, 2015. Biogen Presents New Data from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at Alzheimer’s Association International Conference 2015. Results Demonstrate Statistically Significant Reduction of Beta Amyloid, Dose-Dependent Slowing of Clinical Decline and Acceptable Safety. Contact for Media Inquiries:. June 1, 2016. Aducanumab accepted into EMA's PRIME Program. February 3, 2016. November 10, 2015.

UPGRADE TO PREMIUM TO VIEW 13 MORE

TOTAL PAGES IN THIS WEBSITE

18

LINKS TO THIS WEBSITE

news.uzh.ch

UZH -UZH News - Antikörper gegen Alzheimer

http://www.news.uzh.ch/de/articles/2016/Antikörper-gegen-Alzheimer.html

Alle Artikel / Archiv. Zürcher Zentrum für Integrative Humanphysiologie (ZIHP). Alle Artikel / Archiv. News melden / Kontakt. UZH-Forscher Roger Nitsch ist Pionier in der Alzheimerforschung. In einem Vortrag berichtete er darüber, wie der von seinem Team entwickelte Antikörper Aducanumab die Behandlung der Krankheit revolutionieren könnte. Helen Becker und Sabina Huber-Reggi. Forscht mit seinem Team an Antikörpern gegen Alzheimer: UZH-Professor Roger Nitsch. (Bild: zVg). Der nächste Vortrag im Rahme...

UPGRADE TO PREMIUM TO VIEW 3 MORE

TOTAL LINKS TO THIS WEBSITE

4

SOCIAL ENGAGEMENT

sharer/sharer.php

OTHER SITES

neurima.com

Félicitations ! Votre domaine a bien été créé chez OVH !

Votre domaine neurima.com. A bien été créé chez OVH. Accédez à votre Webmail OVH. Depuis votre Espace Client Web. Consultez la liste des. Vous pouvez dès à présent lui associer un hébergement,. En choisissant la solution la plus adaptée à vos besoins :. Pour héberger vos projets Web :. Site Internet, boutique en ligne,. Alliez la flexibilité du Cloud. À la liberté du dédié. Avec nos solutions VPS clef en main. Accompagnez vos projets Web. Vers une nouvelle étape. Hébergez vos sites Web.

neurimax.com

www.neurimax.com

neurimaziero2015.blogspot.com

Neuri Maziero

Segunda-feira, 27 de abril de 2015. PLANO DE ENSINO 2015. Compartilhar com o Pinterest. Visualizar meu perfil completo. PLANO DE ENSINO 2015. Modelo Simple. Tecnologia do Blogger.

neurime.com

neurime.com - Registered at Namecheap.com

This domain is registered at Namecheap. This domain was recently registered at Namecheap. Please check back later! This domain is registered at Namecheap. This domain was recently registered at Namecheap. Please check back later! The Sponsored Listings displayed above are served automatically by a third party. Neither Parkingcrew nor the domain owner maintain any relationship with the advertisers.

neurimmune.com

Neurimmune - Home

Severe and Rare Diseases. Severe and Rare Diseases. Phase 3 clinical trials. Program for Parkinson in Phase 1. Creating an entirely novel. Generation of drugs with. Excellent safety and efficacy. January 25, 2018. In January 2018, Biogen dosed the first patient in the Phase 2 SPARK study of BIIB054 (anti-alpha-synuclein antibody) in Parkinson's disease. November 9, 2017. Neurimmune Announces Collaboration with Ono Pharmaceutical in Neurodegenerative Diseases Field. October 24, 2017. Neurimmune’s program ...

neurimnamutherapy.com

neurimnamu.therapy

neurimp.eu

Home

Jump to main navigation and login. Email: This email address is being protected from spambots. You need JavaScript enabled to view it. Phone: 34 943 20 67 44. Neurimp Consortium General Meeting. TCES 2015 Annual meeting. 27th European Conference on Biomaterials. 3rd International Symposium on Peripheral Nerve Regeneration. Latest news and project related info. European Society for the Study of Periph. Design, Degradation Mechanism and Long-T. Remarkable and Project related events. TCES 2015 Annual mee.

neurimpulse.com

. : : Neurimpulse : : .

NEURIMPULSE s.r.l. Via Pitagora, 15 -. 35030 Rubano (PD) - Italy. Tel: 39 049 635999 - Fax: 39 049 8973677.

neurimshoes.co.il

מכירת נעליים באינטרנט, נעלי ילדים ילדות נשים גברים צעד ראשון | נעלי נעורים

שנקר 52 חולון 504-7523 (03). כל הזכויות שמורות לנעלי נעורים בע"מ 1965 2018.

neurine--dundee.skyrock.com

neurine--dundee's blog - Une connemara pas comme les autres... - Skyrock.com

Une connemara pas comme les autres. Ponette de dressage (L). Ancienne ponette de cce. Indicé 126 en complet poney. Indicé 115 en dressage chevaux. 8éme sur 32 au Championnat D1P DRESS 2008. 9éme sur 17 au Championnat Amateur 3 jeune 2008. 29/09/2007 at 3:47 PM. 09/11/2009 at 3:51 AM. La suite c'est ici:. Subscribe to my blog! La suite c'est ici:. Http:/ vie-cavaliere.skyblog.com. Posted on Monday, 09 November 2009 at 3:51 AM. On part à Saumur samedi. Posted on Thursday, 29 October 2009 at 11:10 AM. Don't...